Erasca faces fraud investigation after patent infringement claims cause 48% stock plunge

The Schall Law Firm is investigating Erasca, Inc. for potential securities law violations after the company disclosed a patent infringement claim from Revolution Medicines related to its ERAS-0015 drug. This disclosure led to a 48.3% drop in Erasca's stock price on April 28, 2026. The investigation is examining whether Erasca issued false or misleading statements or failed to disclose important information to investors. Shareholders who suffered losses are encouraged to contact the law firm to discuss their rights and possibly join a class action lawsuit.